Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS

Renaissance Technologies LLC purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 81,310 shares of the company’s stock, valued at approximately $1,190,000. Renaissance Technologies LLC owned 0.10% of Corvus Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Sei Investments Co. purchased a new stake in Corvus Pharmaceuticals during the first quarter valued at about $890,000. SEB Asset Management AB purchased a new position in shares of Corvus Pharmaceuticals in the first quarter worth approximately $3,319,000. Bank of New York Mellon Corp raised its holdings in shares of Corvus Pharmaceuticals by 40.8% during the first quarter. Bank of New York Mellon Corp now owns 185,347 shares of the company’s stock valued at $2,712,000 after acquiring an additional 53,719 shares during the period. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Corvus Pharmaceuticals during the first quarter valued at approximately $6,719,000. Finally, Emerald Advisers LLC purchased a new stake in shares of Corvus Pharmaceuticals in the 1st quarter valued at approximately $10,039,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CRVS shares. The Goldman Sachs Group started coverage on shares of Corvus Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $40.00 price objective for the company. Weiss Ratings upgraded Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. LADENBURG THALM/SH SH raised Corvus Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.33.

Key Stories Impacting Corvus Pharmaceuticals

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: An independent analysis examines soquelitinib’s clinical science, commercial market opportunity and fair value, keeping attention focused on the potential upside from Corvus’s lead program. The stock has increased from its 52-week low, suggesting investors continue to assign meaningful value to the drug’s development prospects. Corvus: Evaluating Soquelitinib’s Science, Market Reach, And Fair Value
• Neutral Sentiment: HC Wainwright issued a new FY2030 earnings forecast for Corvus. The article does not provide the estimate, but the long-range projection indicates analysts are continuing to model the company’s path toward commercialization and profitability. FY2030 Earnings Forecast for CRVS Issued By HC Wainwright
• Negative Sentiment: HC Wainwright lowered EPS estimates across multiple periods: FY2026 to a loss of $0.83 from $0.66, FY2027 to a loss of $0.80 from $0.63, FY2028 to a loss of $0.37 from $0.25, and FY2029 to a loss of $0.01 from a profit of $0.07. Quarterly estimates were also reduced, including Q3 2026 to a loss of $0.23 from $0.17 and Q1–Q4 2027 to losses ranging from $0.16 to $0.24 per share. These revisions imply slower progress toward profitability and could pressure sentiment. HC Wainwright Earnings Estimate Revisions for Corvus Pharmaceuticals

Corvus Pharmaceuticals Trading Up 0.6%

NASDAQ CRVS opened at $15.14 on Friday. Corvus Pharmaceuticals, Inc. has a 1-year low of $4.70 and a 1-year high of $26.95. The firm’s fifty day simple moving average is $13.64 and its 200-day simple moving average is $15.14. The company has a market capitalization of $1.27 billion, a PE ratio of -24.82 and a beta of 0.87.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). As a group, analysts predict that Corvus Pharmaceuticals, Inc. will post -0.79 EPS for the current year.

Insider Buying and Selling at Corvus Pharmaceuticals

In other news, Director David Scott Moore purchased 21,700 shares of Corvus Pharmaceuticals stock in a transaction dated Thursday, June 11th. The stock was acquired at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the acquisition, the director directly owned 21,700 shares in the company, valued at $250,201. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 19.70% of the stock is owned by company insiders.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.